Table 2.
Meropenem-Vaborbactam Treatment Features and Outcomes
| Variable | All Infections (n = 342) | BBSIs (n = 172) | LRTI (n = 107) | cUTI (n = 30) | Othera (n = 33) |
|---|---|---|---|---|---|
| MER-VAB treatment variables | … | … | … | … | … |
| Days of treatment—median (IQR) | 11 (7–14) | 11 (7–15) | 11 (7–14) | 7 (3–11) | 14 (9–21) |
| Started empirically | 47 (13.7) | 18 (10.5) | 23 (21.5) | 3 (10.0) | 3 (9.1) |
| Started within 48 h of infection onset | 148 (43.3) | 64 (37.2) | 51 (47.7) | 19 (63.3) | 14 (42.4) |
| Started as second-line therapy | 67 (19.6) | 45 (26.2) | 14 (13.1) | 4 (13.3) | 4 (12.1) |
| Monotherapy regimens | 213 (62.3) | 109 (63.4) | 74 (69.2) | 12 (40.0) | 18 (54.5) |
| Combination regimens with: | 129 (37.7) | 63 (36.6) | 33 (30.8) | 18 (60.0) | 15 (45.5) |
| 1 other active antimicrobial | 98 (28.6) | 47 (27.3) | 24 (22.4) | 18 17 (56.7) | 9 (27.3) |
| ≥2 active antimicrobials | 32 (9.4) | 16 (9.3) | 9 (8.4) | 1 (3.3) | 6 (18.2) |
| Dose adjusted for renal function | 101 (29.5) | 50 (29.1) | 27 (25.2) | 13 (43.3) | 11 (33.3) |
| Prolonged infusion | 231 (67.5) | 123 (71.5) | 68 (63.5) | 21 (70.0) | 19 (57.6) |
| Outcomesb | … | … | … | … | … |
| 30-d all-cause mortality | 108 (31.6) | 57 (33.2) | 35 (32.7) | 4 (13.3) | 12 (36.4) |
| Infection relapsec | 33 (9.6) | 18 (10.5) | 10 (9.4) | 4 (13.3) | 1 (3.1) |
| Development of in vitro MER-VAB resistance | 6 (1.7) | 2 (1.2) | 3 (2.8) | … | 1 (3.1) |
| Adverse reactions | 2 (0.6) | 0 | 1 (0.9) | 1 (3.3) | 0 |
Unless otherwise stated, data are expressed as numbers (%).
Abbreviations: BSI, bloodstream infection; cUTI, complicated urinary tract infection; IQR, interquartile range; LRTI, low respiratory tract infections; MER-VAB, meropenem-vaborbactam.
aOther: 17 abdominal infections, 7 central nervous system infections, 5 osteoarticular infections, 4 skin and soft tissue infections.
bAssessed during the index hospitalization.
cDiagnosed microbiologically during the index hospitalization after the original infection had been classified as microbiologically and/or clinically cured.